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Background: 
An intravenous infusion of lidocaine has been used on numerous occasions to produce analgesia in 
neuropathic pain. In the cases of failed back surgery syndrom, the pain generated as result of abnormal impulse 
from the dorsal root ganglion and spinal cord, for instance as a result of nerve injury may be particularly 
sensitive to lidocaine. The aim of the present study was to identify the effects of IV lidocaine on neuropathic 
pain items of FBSS. 
Methods: 
The study was a randomized, prospective, double-blinded, crossover study involving eighteen patients with 
failed back surgery syndrome. The treatments were: 0.9% normal saline, lidocaine 1 mg/kg in 500 ml normal 
saline, and lidocaine 5 mg/kg in 500 ml normal saline over 60 minutes. The patients underwent infusions 
on three different appointments, at least two weeks apart. Thus all patients received all 3 treatments. Pain 
measurement was taken by visual analogue scale (VAS), and neuropathic pain questionnaire. 
Results: 
Both lidocaine (1 mg/kg, 5 mg/kg) and placebo significantly reduced the intense, sharp, hot, dull, cold, 
sensitivity, itchy, unpleasant, deep and superficial of pain. The amount of change was not significantly different 
among either of the lidocaine and placebo, or among the lidocaine treatments themselves, for any of the pain 
responses, except sharp, dull, cold, unpleasant, and deep pain. And VAS was decreased during infusion in all 
3 group and there were no difference among groups.
Conclusions: 
This study shows that 1 mg/kg, or 5 mg/kg of IV lidocaine, and palcebo was effective in patients with 
neuropathic pain attributable to FBSS, but effect of licoaine did not differ from placebo saline. (Korean J Pain 
2012;  25:  94-98)
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INTRODUCTION
There are many cause of failed back surgery syndrome 
(FBSS) [1]. The e tio l ogy is that a bou t 58% later a l can a l 
stenosis,  7-14%  central  stenosis,  12-16%  recurrent  disc 
hernation, 6-16% arachnoiditis, and 6-8% epidural fibrosis 
[2]. Other less common causes include nerve injury during 
surgery (neuropathic pain), chronic mechanical pain, pain-
ful segment disc above a fusion, pseudoarthrosis, foreign 
body, and surgery performed at the wrong level. 
Among those causes, neuropathic pain observed 5-9% 
in patients [2,3]. There are several potential mechanisms 
for  neuropathic  pain  after  spine  surgery.  A  nerve  root 
could have been damaged prior to surgery because of ei-
ther sudden injury or prolonged compression from fora-
m in a l  s t e n o s is  o r  d is c  h e r n i a t i o n.  A l t e r n a t i v e l y ,  a  n e rv e 
could be damaged during the surgery itself. After then, an 
ectopic impulse generated within injured nerve or dorsal 
root ganglion. These abnormal pulses may be associated 
with neuropathic pain.
In  generally,  tricyclic  antidepressants,  dual  reuptake 
inhibitors of serotonin and norepinephrine, calcium channel 
alpha(2)-delta  ligands  (i.e,  gabapentin  and  pregabalin), 
and  topical  lidocaine  were  recommended  as  first-line 
treatment options on the basis of the results of randomized 
clinical trials [4]. 
An intravenous infusion of lidocaine has been used on 
numerous occasions to produce analgesia in neuropathic 
pain [5-7]. In the cases of FBSS, the pain generated as 
result of abnormal impulse from the dorsal root ganglion 
and spinal cord, for instance as a result of nerve injury 
may be particularly sensitive to lidocaine [8-10].
Lidocaine is a local anesthetic of the amide type so-
dium channel blocker and produces analgesia by blockade 
of peripheral and central sodium ion gate channels, includ-
ing the spinal dorsal horn [10] or inhibition of neural ec-
topic discharges [11]. 
A variable pain qualities and quantities reflect differing 
underlying pain mechanisms and might therefore predict 
differing response to treatment [12]. In previous study, the 
pain intensity reductions in response to intravenous lido-
caine are different according to pain qualities [13]. Also a 
open label clinical trial of lidocaine patch 5% for chronic 
neuropathic and nociceptive pain provide different reduc-
tion of each of the neuropathic pain scale items [14].
H o w e v e r ,  n o  p r e v i o u s  s t u d i e s  h a v e  p r e v i o u s l y  a d -
d r es se d  t h e  e ff i c a c y  o f I V li d o c a in e o n t h e n e u r o p a t h i c 
items in patients with failed back surgery syndrome (FBSS). 
The aim of the present study was to evaluate the effi-
cacy of IV lidocaine on pain and its specific effects on the 
neuropathic pain scale in patients with neuropathic pain 
caused by lumbar surgery. 
MATERIALS  AND  METHODS
W e  p e r f o r m e d  a  r a n d o m i z e d ,  p r o s p e c t i v e ,  d o u b l e -  
blinded, crossover study involving eighteen who received 
three treatments. The study was conducted with the full 
approval of the Institutional Review Board. All patients had 
long-standing (＞2 years) neuropathic pain; neuropathic 
pain suspected by a board certified specialist who assessed 
the patients based on the presence of allodynia, hyper-
algesia,  hyperpathia,  hyperesthesia  and  hypoesthesia. 
Inclusion criteria for FBSS were: 1) the patients had under-
gone lumbar surgery. 2) MRI showed no evidence of ana-
tomical abnormalities (stenosis, recur, arachnoiditis, and 
instability); 3) EMG showed neuropathy; 4) all patients had 
to have failed standard pharmacological or interventional 
treatments,  failure  was  defined  as:  1)  no  response  to 
treatment or; 2) no lasting relief of pain (＜2 months); and 
3) persistence, progression of the syndrome.
Patients with known contraindication such as allergies 
to lid ocaine, seizure disorder, a history of substance or 
drug abuse, psychiatric illness, or suspected somatoform 
pain disorder were excluded. And a history of gastric or 
duodenal  ulcer,  vascular  disease,  arrhythmia,  ischemic 
heart disease, or renal insufficiency was excluded. 
E i g h t e e n  p a t i e n t s  r e c e i v e d  e a c h  o f  f o l l o w i n g  i n t r a-
venous infusion over 1 hour at 2 weeks apart: normal saline 
placebo, lidociane 1 mg/kg, and lidocaine 5 mg/kg in 500 
ml normal saline at 60 ml/hr initially, and then titrated in-
fusion speed while keep the heart rate ＜ 130 rates/min 
or 160 mmHg ＞ systolic blood pressure ＞ 85 mmHg. 
The  patient  underwent  infusions  on  three  different 
days. Each day, the subject received one of the three in-
fusions in randomized order. Both the patient and person 
d o i n g  t h e  p a i n  e v a l u a t i o n s  w e r e  b l i n d e d  t o  t h e  d r u g  
infused. Pain intensity was assessed using visual analogue 
scale (V AS) (0-10/10, 0; no pain, 10: the most pain) and 
neuropathic pain scales (NPS). A VAS scores were meas-
ured at just before injection, at every 10 minutes up to 60 
minutes during injection, and then at 8 hrs, 16 hrs, and 96 Korean J Pain Vol. 25, No. 2, 2012
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Fig. 1. The effects of lidocaine on pain (visual analogue 
scale [VAS] score) measured by every 10 minutes for 60 
minutes during injection and after the injection.
Table 1. Age and Duration of Pain
Patient characteristics (N = 18)
Age (yr) (range)
Duration of pain (yr) (range)
M：F
 42.8 ± 9.4 (23−55)
6.1 ± 7.2 (1−9)
5：13
All variables are presented as means ± SD (range).
Table 2. Changes of Neuropathic Pain Scales
N = 18 Control P values 1 mg/kg P value 5 mg/kg P value
Intense
Sharp
Hot
Dull
Cold
Sensitivity
Itching
Unpleasant
Deep pain
Superficial pain
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
7.8 (1.4)
6.1 (2.2)
6.7 (1.9)
4.9 (2.4)
6.0 (2.4)
3.9 (2.5)
7.7 (1.3)
5.9 (2.3)
6.1 (2.0)
3.2 (1.9)
6.2 (2.1)
5.0 (2.6)
3.8 (2.6)
1.8 (1.5)
7.3 (1.3)
5.1 (2.0)
7.3 (1.6)
5.9 (2.2)
6.3 (1.9)
4.8 (2.3)
0.003
0.001
0.000
0.001
0.000
0.001
0.002
0.002
0.006
0.005
7.7 (1.0)
5.9 (2.0)
6.8 (2.1)
5.2 (2.6)
5.1 (2.2)
4.2 (2.6)
6.8 (2.2)
5.7 (2.7)
4.9 (2.9)
2.9 (2.2)
6.9 (2.3)
5.2 (2.9)
2.9 (2.0)
2.1 (2.0)
7.9 (0.6)
6.2 (2.1)
7.2 (1.1)
6.9 (2.3)
6.2 (1.8)
5.2 (3.0)
0.001
0.001
0.033
0.011
0.001
0.001
0.026
0.002
0.777
0.039
7.0 (1.3)
5.0 (2.9)
6.7 (2.4)
4.0 (2.5)
5.0 (2.3)
3.2 (2.0)
6.9 (1.6)
4.1 (1.8)
4.1 (2.5)
3.2 (2.2)
6.8 (2.1)
4.9 (2.5)
3.2 (1.9)
1.8 (1.4)
7.0 (1.2)
6.1 (2.0)
7.8 (1.4)
5.9 (2.1)
5.9 (2.1)
4.9 (2.2)
0.001
0.000
0.003
0.000
0.019
0.003
0.001
0.002
0.002
0.036
All variables are presented as means, (SD).
24 hrs after injection (The subjects were asked to take 
home a diary in which they would report on V AS). 
During the infusions, the subjects’ blood pressure was 
r e c o r d e d  e v e r y  5  m i n u t e s  a n d  e l e c t r o c a r d i o g r a p h y , w a s  
monitored  continuously.  Following  the  completion  of  the 
study, all patients received a one month follow-up. 
All variables are presented as means ± SD. Wilcoxon’s 
signed rank test and the Mann-Whitney test were used 
for comparison of paired and unpaired data, respectively. 
Repeated measures analysis of variance (ANOVA) was used 
for comparisons of VAS. A P ＜ 0.05 was considered sig-
nificant for all analyses. SPSS version 17 was used for all 
analyses (SPSS Inc., Chicago, IL).
RESULTS
Eighteen patients completed the study. Of these, thir-
teen (72%) were female. Descriptive statistics are shown 
in T able 1. 
The effect of lidocaine infusion on neuropathic pain is 
shown in Table 2, and Fig. 1. Figure 1 shows the VAS scores 
for pain plotted against the time of the three infusions. 
The VAS scores before starting were compared to the score 
at the end of the infusion and demonstrated a significant 
decrease with all three infusions (P = 0.006). Mann-Whitney CH Park, et al / Effect of Intravenous Lidocaine on NPS 97
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Table 3. Descriptive Statistics on Amount of Change Pre-Post Treatment
Control 1 mg/kg 5 mg/kg P
Intense
Sharp
Hot
Dull
Cold
Sensitivity
Itchy
Unpleasant
Deep pain
Superficial pain
−20.0 (29.6)
−25.0 (28.1)
−31.2 (27.9)
−23.3 (27.7)
−42.7 (45.1)
−18.9 (26.1)
−36.4 (48.1)
−28.6 (26.5)
−15.5 (32.8)
−17.3 (49.0)
−23.2 (23.3)
−23.2 (24.4)
−15.4 (37.7)
−22.2 (28.5)
−37.7 (43.9)
−25.2 (26.9)
−12.4 (84.2)
−21.5 (25.2)
  −2.6 (33.9)
−21.4 (34.9)
−27.3 (31.9)
−35.0 (29.8)
†
−27.2 (36.2)
−33.5 (43.7)
†
−24.1 (36.1)*
−24.6 (32.8)
−36.6 (30.9)
−11.6 (31.6)
†
−22.7 (31.5)
†
−13.7 (30.6)
0.352
0.037
0.055
0.019
0.018
0.349
 0.3000
0.045
0.012
0.934
All variables are presented as means, (SD). *P  ＜ 0.05 compared with control, 
†P  ＜ 0.05 compared with 1 mg/kg.
t e s t  d e m o n s t r a t e d  t h a t  t h e r e  w a s  n o  d i f f e r e n c e  i n  V A S 
scores among the three infusions at either the start of the 
infusions or the end of the infusions. 
For all 3 treatments, changes from before to after the 
infusions were significant in NPS (Table 2). The amount of 
change was not significantly diff erent between either of 
the lidocaine and placebo, or between the lidocaine treat-
ments themselves, for any of the pain responses, except 
sharp, dull, cold, and deep pain (Table 3). Cold pain was 
most changed in placebo. 
DISCUSSION
This double-blind, placebo-controlled study shows that 
placebo and IV lidocaine can produce significant analgesic 
effects and special effects on each items of NPS in a group 
of patients with neuropathic pain attributable to FBSS. 
In the present study, both lidocaine and saline placebo 
reduced in each of the NPS items. Our expectation was 
that IV lidocaine and higher dosage of lidocaine would cor-
relate with more reduce of items of NPS and higher pain 
relief. However, in our study, NPS reduction was achieved 
in all groups (1 mg/kg or 5 mg/kg of lidocaine and placebo). 
In addition, the amount of changes in pain after treatment 
did not differ significantly among the 3 treatments, except 
for sharp, dull, cold and deep pain. We could not explain 
this finding. However, after 5 mg/kg, there were signi-
ficantly changes in sharp, dull, and deep pain. The cold 
pain was most reduction in saline placebo than lidocaine 
in this study. One controlled clinical trial reported that in-
fusion of lidocaine at a dose of 5 mg/kg/h significantly de-
creased  of  pain  intensity  compared  with  placebo  [15]. 
Previous studies have reported results regarding the inter-
action of pain quality and responsiveness to sodium chan-
nel blocker [13]. The patients with high levels of heavy pain 
quality have significantly a greater decrease in V AS pain 
intensity [13]. However, our study was inconsistent with 
this study. We postulated that saline placebo affect to NPS. 
This may suggest that the mechanism of pain was hetero-
geneous in spite of the single disease.
The analgesic effects of lidocaine observed in our pa-
tients did not different among 1 mg/kg and 5 mg/kg of 
lidocaine.Results of the present study which VAS was de-
c r e a s e d  c o r r e s p o n d  w i t h  t h e  r e s u l t s  o f  e a r l i e r  s t u d i e s  
[6,7,16,17]. This suggests that lidocaine produces a dose- 
related reduction of afferent activity from dorsal root gan-
glion [8-10]. In addition, analgesia produced by lidocaine 
appears to result from suppression of tonic neural dis-
c h a r g e  i n  i n j u r e d  p e r i p h e r a l  A - d e l t a  a n d  C  f i b e r  n o c i-
ceptors [8].
The effective dose range of systemic lidocaine is com-
parable among different neuropathic pain conditions. The 
range of the lidocaine plasma level is from 0.62 to 5.0 
μg/ml [18]. It may be that a minimum therapeutic plasma 
level for lidocaine was reached at 1 mg/kg of lidocaine [7]. 
Moreover, the free concentration of lidocaine showed no 
better correlation with the onset of analgesia or the at-
tainment of complete analgesia than the serum concen-
tration of lidocaine. Ferrante et al. [17] suggested that the 
m e c h a n i s m  o f  a n a l g e s i a  f r o m  I V  l i d o c a i n e  i s  n o t  b e i n g 
based upon a conventional concentration-effect relation-
ship and there was not a direct relationship between total 
or free lidocaine levels and the effect on neuropathic pain 
[15]. However, we did not determine the blood levels of li-98 Korean J Pain Vol. 25, No. 2, 2012
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docaine, 
In the present study, equal pain reduction was seen 
in both lidocaine and the saline placebo. It is possible that 
because of the small sample studied, we cannot entirely 
exclude the possibility that lack of difference between lido-
canie and placebo is due to a type 2 error. In Baranowski 
et al’s study [7] there was a significant reduction in con-
stant pain with placebo and he suggested that constant 
pain  occurs  less  as  a  result  of  peripheral  stimulation. 
Furthermore Tremont-Lukats et al. [15] reported that lido-
caine at lower infusion rates (1 mg/kg, and 3 mg/kg) was 
no better than placebo in relieving pain. However, the au-
thor did not conclude that doses of lidocaine lower than 
5 mg/kg/h are not effective and not different from placebo. 
In painful neuropathy in cancer patients study [16], neither 
lidocaine (5 mg/kg) nor placebo reduce pain intensity or 
consumption of analgesics significantly. The author sug-
gested that it is a different effect on mechanical and other 
somatosensory input by touch stimuli still evoking activity 
in the dorsal horn cell. 
There were se v eral limitations to the presen t study. 
Fisrt, we identified were not corroborated with any compli-
c a t i o n s ,  S e c o n d ,  f o l l o w - u p  w a s  l e s s  t h a n  2 4  h o u r s ,  s o 
there were no result from mid- or long-term follow periods. 
I n c o n c l u s i o n,  t h i s s t u d y s h o w s t h a t  1 m g/ kg,  o r 5 
mg/kg of IV lidocaine, and placebo was effective to pa-
tients with neuropathic pain attributable to FBSS, but ef-
fect of lidocaine did not differ from placebo. We did not 
explain placebo effect. Further adequately powered trials 
should  be  established  whether  saline  have  same  with 
lidocaine.
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